MX2009010667A - Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. - Google Patents
Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.Info
- Publication number
- MX2009010667A MX2009010667A MX2009010667A MX2009010667A MX2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A MX 2009010667 A MX2009010667 A MX 2009010667A
- Authority
- MX
- Mexico
- Prior art keywords
- dimers
- cancer agents
- compounds
- useful
- smac mimetic
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000000539 dimer Substances 0.000 title 1
- 229940075439 smac mimetic Drugs 0.000 title 1
- 239000013638 trimer Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010065954 SMAC peptide Proteins 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91147207P | 2007-04-12 | 2007-04-12 | |
| US95249307P | 2007-07-27 | 2007-07-27 | |
| PCT/US2008/060140 WO2008128121A1 (en) | 2007-04-12 | 2008-04-11 | Smac mimetic dimers and trimers useful as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010667A true MX2009010667A (es) | 2010-02-24 |
Family
ID=39864357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010667A MX2009010667A (es) | 2007-04-12 | 2008-04-11 | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8642554B2 (enExample) |
| EP (1) | EP2079309B1 (enExample) |
| JP (1) | JP5454943B2 (enExample) |
| CN (1) | CN101668426B (enExample) |
| AU (1) | AU2008240153B2 (enExample) |
| BR (1) | BRPI0810178A2 (enExample) |
| CA (1) | CA2684169C (enExample) |
| MX (1) | MX2009010667A (enExample) |
| NZ (1) | NZ580313A (enExample) |
| WO (1) | WO2008128121A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006020060A2 (en) * | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| PL1851200T3 (pl) | 2005-02-25 | 2014-06-30 | Tetralogic Pharm Corp | Dimeryczne inhibitory IAP |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| US7589118B2 (en) | 2005-10-25 | 2009-09-15 | Aegera Therapeutics, Inc. | IAP BIR domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| CN101516904A (zh) * | 2006-07-24 | 2009-08-26 | 泰特拉洛吉克药业公司 | 二聚的iap拮抗剂 |
| US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5452223B2 (ja) * | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| EP2156189A1 (en) * | 2007-05-07 | 2010-02-24 | Tetralogic Pharmaceuticals Corp. | Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
| AR066528A1 (es) | 2007-05-10 | 2009-08-26 | Array Biopharma Inc | Peptidos inhibidores de la replicacion del virus de la hepatitis c |
| US20110177060A1 (en) * | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| CA2740193A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| RS52854B (sr) | 2009-06-11 | 2013-12-31 | Abbvie Bahamas Limited | Inhibitori hepatitis c virusa |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| EP2493879B1 (en) * | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| CN102985439B9 (zh) | 2010-02-12 | 2016-08-03 | 制药科学股份有限公司 | Iap bir结构域结合化合物 |
| UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| WO2014055461A1 (en) * | 2012-10-02 | 2014-04-10 | Bristol-Myers Squibb Company | Iap antagonists |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN104710510A (zh) * | 2013-12-12 | 2015-06-17 | 深圳先进技术研究院 | Smac蛋白二聚拟合物及其鉴定方法 |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6768522B2 (ja) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10398702B2 (en) * | 2016-05-09 | 2019-09-03 | Hoffmann-La Roche Inc. | Dimeric compounds |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| BR112019012682A2 (pt) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | moléculas quiméricas visando a proteólise de egfr e métodos associados de uso |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| JP7455141B2 (ja) * | 2019-04-05 | 2024-03-25 | へパジーン セラピューティクス （エイチケイ） リミテッド | アポトーシスタンパク質の阻害剤の二価拮抗薬 |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| CN118986983A (zh) | 2019-08-26 | 2024-11-22 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| TW202227397A (zh) | 2020-09-03 | 2022-07-16 | 英商歐瑞夏治療公司 | 雙環的－雜環衍生物及相關用途 |
| WO2022056368A1 (en) | 2020-09-14 | 2022-03-17 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| US20240309557A1 (en) * | 2021-01-27 | 2024-09-19 | Unm Rainforest Innovations | Pyrazole and pyrazoline-containing peptides, high throughput click libraries, and methods |
| US11814367B2 (en) | 2021-03-15 | 2023-11-14 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof |
| WO2023239422A2 (en) | 2021-10-22 | 2023-12-14 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
| KR20250170567A (ko) * | 2023-04-17 | 2025-12-05 | 아벨로스테라퓨틱스 주식회사 | 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5387584A (en) | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| SE9603466D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
| US6916846B2 (en) * | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
| KR100850727B1 (ko) | 2000-11-02 | 2008-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90에 결합하기 위한 소분자 조성물 |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| JP4541882B2 (ja) * | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤 |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| WO2005084317A2 (en) * | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| SG152225A1 (en) | 2004-04-07 | 2009-05-29 | Novartis Ag | Inhibitors of iap |
| RS53734B1 (sr) | 2004-07-02 | 2015-06-30 | Genentech Inc. | Inhibitori iap |
| WO2006020060A2 (en) * | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| CN101146803A (zh) | 2004-12-20 | 2008-03-19 | 健泰科生物技术公司 | Iap的吡咯烷抑制剂 |
| PL1851200T3 (pl) * | 2005-02-25 | 2014-06-30 | Tetralogic Pharm Corp | Dimeryczne inhibitory IAP |
| JP4954983B2 (ja) * | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
-
2008
- 2008-04-11 NZ NZ580313A patent/NZ580313A/en not_active IP Right Cessation
- 2008-04-11 JP JP2010503257A patent/JP5454943B2/ja not_active Expired - Fee Related
- 2008-04-11 BR BRPI0810178-7A patent/BRPI0810178A2/pt not_active IP Right Cessation
- 2008-04-11 US US12/101,733 patent/US8642554B2/en not_active Expired - Fee Related
- 2008-04-11 CA CA2684169A patent/CA2684169C/en not_active Expired - Fee Related
- 2008-04-11 MX MX2009010667A patent/MX2009010667A/es active IP Right Grant
- 2008-04-11 WO PCT/US2008/060140 patent/WO2008128121A1/en not_active Ceased
- 2008-04-11 CN CN200880011260.1A patent/CN101668426B/zh not_active Expired - Fee Related
- 2008-04-11 AU AU2008240153A patent/AU2008240153B2/en not_active Ceased
- 2008-04-11 EP EP08745697.6A patent/EP2079309B1/en not_active Withdrawn - After Issue
-
2014
- 2014-01-16 US US14/156,522 patent/US20140127155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101668426A (zh) | 2010-03-10 |
| NZ580313A (en) | 2011-11-25 |
| CN101668426B (zh) | 2014-01-15 |
| US8642554B2 (en) | 2014-02-04 |
| US20090104151A1 (en) | 2009-04-23 |
| EP2079309A4 (en) | 2011-07-06 |
| JP5454943B2 (ja) | 2014-03-26 |
| CA2684169A1 (en) | 2008-10-23 |
| CA2684169C (en) | 2012-06-19 |
| AU2008240153B2 (en) | 2013-01-31 |
| EP2079309B1 (en) | 2015-11-11 |
| WO2008128121A1 (en) | 2008-10-23 |
| EP2079309A1 (en) | 2009-07-22 |
| JP2010523717A (ja) | 2010-07-15 |
| BRPI0810178A2 (pt) | 2014-09-23 |
| AU2008240153A1 (en) | 2008-10-23 |
| US20140127155A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010667A (es) | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. | |
| MX2008012053A (es) | Promotores de apoptosis de molecula pequeña. | |
| EP2493879A4 (en) | DIMERE SMAC MIMETIKA | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
| EA201401107A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
| PH12012500391A1 (en) | Conjugates of pyrrolo [1,4] benzodiazepine dimers as anticancer agents | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| JO3438B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| MX2014005411A (es) | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| IN2014CN04961A (enExample) | ||
| ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
| MX2009005712A (es) | Antagonistas de receptor de orexina de diazepam sustituido. | |
| MX375439B (es) | Moleculas de union cd37 y sus inmunoconjugados. | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| MX2014003689A (es) | Anticuerpos contra tl1a y sus usos. | |
| EA201070270A1 (ru) | Пептиды с пониженным уровнем образования димеров | |
| IN2012DN00640A (enExample) | ||
| CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
| CL2011001214A1 (es) | Dimero de proteina similar a anticuerpo que comprende un decimo dominio de fibronectina de tipo iii (10fn3) que se une a igf-ir; unido covalentemente o no covalentemente con un 10fn3 que se une a egfr; composicion farmacéutica que lo comprende; uso de dicha composicion para tratar transtornos hiperproliferativo. | |
| UA106900C2 (uk) | Агоністичний dr5-зв'язувальний поліпептид | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |